Autres langues Alamar Biosciences, Inc.

Actions

ALMR

US0109111056

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq 22:00:00 27/08/2026			Varia. 5j.	Varia. 1 janv.
33,00 ^USD	-3,17%		-7,15%	-

11/08	Les plus fortes hausses de la mi-séance	MT
11/08	Alamar Biosciences, Inc. : BofA Securities toujours neutre sur le dossier	ZM

Autres langues

11/08	Top Midday Gainers
11/08	Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures
10/08	Alamar: Q2 Earnings Snapshot
10/08	Alamar Biosciences Q2 Loss Narrows, Revenue Rises
10/08	Alamar Biosciences, Inc. Provides Revenue Guidance for the Third Quarter of 2026
10/08	Earnings Flash (ALMR) Alamar Biosciences Posts Q2 Loss Per Share $0.22, vs. FactSet Est of $0.31 Loss
10/08	Earnings Flash (ALMR) Alamar Biosciences, Inc. Reports Q2 Revenue $29.4M, vs. FactSet Est of $25.9M
10/08	Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
10/08	Alamar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Alamar Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026
10/08	Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
10/08	Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
10/08	Alamar Biosciences, Inc. Expands Global Partnership with Alzheimer?s Disease Data Initiative and Gates Ventures
28/07	Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07	Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07	Alamar Biosciences Launches NULISAseq Immune 340 Panel For Comprehensive Profiling Of The Immune Proteome
15/07	Alamar Biosciences, Inc. Announces Board and Committee Changes
14/07	Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
13/07	Alamar Biosciences Partners With Research Universities on Neurodegenerative Biomarker Project
13/07	Alamar Biosciences Partners With Research Universities To Launch National Proteomics Initiative Using NULISAseq Neuro 220 Panel
13/07	Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
10/07	Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
07/07	Alamar Biosciences Launches the First Multiplexed Blood-Based Immunoassay for eMTBR-Tau
07/07	Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
29/06	Alamar Biosciences, Inc.(NasdaqGS:ALMR) added to Russell 2000 Index